1
Objective. To examine the prevalence of a 1 -antitrypsin deficiency (AATD) in rheumatoid arthritis (RA), and to determine whether AATD is associated with higher levels of rheumatoid factor (RF), antinuclear antibodies (ANAs), and anti-citrullinated peptide autoantibodies (ACPAs).
Methods. RF, ANAs, and ACPAs were measured by standard immunoturbidimetry, immunofluorescence assay, and enzyme-linked immunosorbent assay, respectively. Characterization of AAT phenotypes was performed by isoelectric focusing and immunofixation. The chisquare test with Yates' correction and the Mann-Whitney U test were used to assess the prevalence of alleles associated with AATD in RA and to compare mean antibody titers, respectively.
Results. Of 246 patients with RA, 24 who were heterozygous for AATD were identified, with no statistically significant difference in the prevalence of AATD between RA patients and the general population (P 5 0.39). A positive association between heterozygosity for AATD and the production of ACPAs was observed (P < 0.0001), with increased ACPA titers recorded in the AATD RA cohort compared with the general population (P 5 0.01).
Conclusion. AAT heterozygous status in RA is strongly associated with positive ACPAs and may define a distinct subset of patients with increased disease severity.
Rheumatoid arthritis (RA) is a common autoimmune disease that is characterized by synovial inflammation and hyperplasia, with consequent soft tissue and bone destruction. In .70% of cases, anti-citrullinated peptide autoantibodies (ACPAs) are known to play a direct role in activating and perpetuating the aberrant immune response (1) . Although it is known that such antibodies appear in the sera of asymptomatic individuals up to a decade before the onset of RA, the mechanisms underlying the development of RA are not completely understood.
It is clear that a series of events leads to the development of a proinflammatory environment in RA synovium. One possible contributor is a deficient state of the ubiquitous protease inhibitor (Pi) a 1 -antitrypsin (AAT). AAT is a glycosylated hepatocyte-derived protein that plays a pivotal role in maintaining the protease-antiprotease balance throughout the body and is a key component of synovial fluid (2) . Furthermore, independent of antiprotease activity, AAT possesses several important antiinflammatory and immune regulatory properties. In this regard, AAT has been shown to modulate signaling by interleukin-8 (IL-8), tumor necrosis factor (3), leukotriene B 4 (4) , interferon-g, and IL-1b (5), and to lower plasma levels of neutrophil granule antigenic proteins and IgG class anti-lactoferrin autoantibodies, all of which are important proinflammatory mediators associated with RA pathogenesis (6) .
AAT deficiency (AATD) is an autosomalcodominant condition characterized by low levels of AAT in the systemic circulation. The ATT protein is encoded by the polyalleic SERPINA1 gene. The fully functional M allele accounts for ;95% of all SERPINA1 alleles, while the severe deficiency Z allele accounts for 1-2%, and the mild deficiency S allele accounts for ;5%. The heterozygous PiMS and PiMZ AATD phenotypes are associated with circulating AAT levels of ;80% and ;60% of the normal concentration, respectively. AATD manifests clinically as early-onset panacinar emphysema (7) but also is recognized as a systemic condition with a number of established manifestations, including liver disease and necrotizing panniculitis. Furthermore, anti-proteinase 3 (anti-PR3)-positive (classic antineutrophil cytoplasmic antibody-positive) vasculitis has been reported in AATD, with the prevalence of a Z allele in vasculitis cohorts being significantly higher than the frequency in healthy individuals (8) . With regard to RA, the true relationship with AATD has long been debated, with early studies suggesting a higher incidence of AATD in RA patients than in the general population (9,10); however, further studies have not corroborated this association (11, 12) . In the current study, we determined the AAT phenotype of one of the largest RA cohorts to date to investigate whether the prevalence of alleles associated with AATD was higher in RA patients compared with the general population.
PATIENTS AND METHODS
Patient recruitment. Patients (n 5 246) were recruited from the Rheumatology Departments at St. Vincent's University Hospital, Beaumont Hospital, and Mater Misericordiae Hospital in Dublin, Ireland. All patients met the American College of Rheumatology/European League Against Rheumatism criteria for RA (13) and provided fully informed written consent. The general population was represented by a cohort of 1,100 randomly selected individuals from the national electoral register previously used to determine the overall prevalence of AATD in Ireland (14) . The study was approved by the respective institutional ethics committees, and research was performed in accordance with the Declaration of Helsinki.
Phenotypic analysis of AAT and autoantibody measurements. Isoelectric focusing to establish the AAT phenotype was performed using a Sebia Hydrasys platform as previously described (15) . IgG ACPAs were measured using a Phadia 250 Laboratory System (Thermo Scientific) and a commercially available second-generation anti-cyclic citrullinated peptide (anti-CCP) enzyme-linked immunosorbent assay (ELISA). An anti-CCP test result of ,10 units/ml was considered negative. Two upper limits (250 units/ml and 340 units/ml) of sensitivity for the anti-CCP test were reported by the hospital laboratories. IgM rheumatoid factor (RF) was detected using a Phadia 250 Laboratory System with a cutoff of 20 IU/ml, above which subjects were considered to be RF positive. Antinuclear antibodies (ANAs) were detected by indirect immunofluorescence with HEp-2 cells, using a QUANTA Lyser 160 ELISA/IFA Processor. ANAs were considered negative if detected at a dilution of ,1:100.
Statistical analysis. The chi-square test with Yates' correction was used to determine differences in the prevalence of alleles associated with AATD in RA patients compared with the general population and to determine the association with antibody positivity in these populations. The Mann-Whitney U test was used to analyze the mean antibody titers. GraphPad Prism 4.0 and SPSS version 18.0 were used for statistical analysis.
RESULTS
A total of 246 patients with RA were included in this study. Among these, 222 (90.24%) were identified as having the PiMM phenotype for AAT, while 15 (6.1%) patients were identified as PiMS (8) (Figure 1A) . No RA patients homozygous for the Z allele were identified, but 9 Figure 1 . Analysis of a 1 -antitrypsin (AAT) mutations in rheumatoid arthritis (RA). A, AAT phenotyping was performed using a Hydragel AAT Isofocusing kit (Sebia), which separates various isoglycoforms of AAT in plasma on the basis of their isoelectric point in a pH gradient between 4.2 and 4.9. Isoelectric focusing patterns for MM, MS, and MZ are shown. B, A cohort of 1,100 randomly selected individuals (general) and 246 RA patients were screened for AAT deficiency. Normal (protease inhibitor [Pi] MM) and abnormal (PiMS and PiMZ) human AAT phenotypes were recorded. There was no statistically significant difference in the prevalence of AAT deficiency in RA patients compared with the general population.
(3.66%) were identified as having the PiMZ phenotype. There was no statistically significant difference in the prevalence of AATD between RA patients and the general population (P 5 0.39) ( Figure 1B ). Turning our attention to the most common pathologic allele, there was no statistically significant difference in the Z allele frequency between the RA cohort (0.0183) and the general population (0.0128; P 5 0.75).
To establish whether abnormal AAT phenotypes were associated with increased autoantibody production, ACPA titers were compared. ACPA titers were available for 179 RA patients who had been phenotyped for AAT (164 had the PiMM phenotype, 9 had the PiMS phenotype, and 6 had the PiMZ phenotype). Among patients with the PiMM phenotype, 86 of 164 (52.4%) were ACPA positive, while all 6 (100%) of the individuals with the PiMZ phenotype had positive ACPA titers. There was a statistically significant difference between the groups, identifying a positive association between the presence of a single Z allele for AAT and the production of ACPAs (P , 0.0001) (Figure 2 ). Moreover, among RA patients, the mean ACPA titer in the PiMM group was significantly lower at 108.8 6 35.5 units/ml (mean 6 SD) compared with 255.5 6 250 units/ml in the PiMZ cohort (P 5 0.01) ( Figure 3A ). There was no statistically significant difference in RF titers in seropositive RA patients when PiMM (266.4 IU/ml) was compared with PiMZ (358.2 IU/ml) (P 5 0.63) ( Figure 3B) . Similarly, when ANA titers were compared between the PiMM and PiMZ phenotypes, there was no statistically significant difference, but a trend toward higher titers was observed in the PiMZ group (mean titer 1:1,248 versus 1:630.5 in the PiMM cohort (P 5 0.44) ( Figure 3C ). Of note, a mean ACPA level of 116.1 units/ml was recorded in patients with the PiMS phenotype, but this value was not statistically significantly different compared with that in patients with the PiMM phenotype (P 5 0.982) (results not shown). Collectively, these results demonstrate that the presence of 1 PiZ allele in patients with RA leads to increased production of autoantibodies, in particular, high ACPA levels.
DISCUSSION
Previous studies have assessed the relationship between AATD and RA and presented opposing data for (9,10) and against (11, 12) this relationship. By using a phenotyping approach for AATD that is more precise than those previously used, we have readdressed the question of an association between AATD and RA. Our study demonstrated no increase in the prevalence of AATD in RA patients compared with the general population. However, the presence of abnormal AAT phenotypes and the reduced levels of AAT have previously been shown to drive autoantibody production systemically (15) .
In this study, we demonstrated that the AATD PiMZ phenotype was associated with ACPA production and significantly higher titers of antibody compared with non-AATD-deficient phenotypes. Although there was no statistically significant increase in the levels of ANAs or RF in patients with the PiMZ phenotype, there was a trend toward higher titers in this group. These findings, coupled with the association of anti-PR3 antibody-associated vasculitis in AATD (8) , are suggestive of a role for circulating AATD in modulating adaptive immune responses and are consistent with reductions in autoantibody levels in models of autoimmunity after AAT therapy (16) .
Unfortunately, because AATD is rare and often is undiagnosed, studies in RA registries may have poor sensitivity for identifying a genetic link between AATD and RA. Nonetheless, our results indicate that patients with RA who are heterozygous for the Z allele may be predisposed to increased autoantibody production. While there was no increased prevalence of the Z allele of AAT in RA, this allele may impact the symptoms and severity of RA. An association between AATD and an increase in the numbers of specific autoantibodies in comorbid autoimmune diseases other than RA requires investigation.
